Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

FDA's Proposed Osteoporosis Definition For PTH Trials Questioned By Lilly

  • News

Executive Summary

FDA's proposed limitations on clinical trial eligibility for parathyroid hormone osteoporosis studies are too restrictive, Lilly said in Aug. 4 comments on FDA's "Development of Parathyroid Hormone for the Prevention and Treatment of Osteoporosis" draft guidance.

You may also be interested in...



Lilly Oritavancin Antibacterial Agent NDA Submission Targeted For 2003

Lilly expects to file an NDA for the antibacterial glycopeptide oritavancin by 2003, Senior VP-Pharmaceutical Products John Lechleiter, PhD, told the J.P. Morgan H&Q Healthcare Conference in San Francisco Jan. 8.

Lilly Oritavancin Antibacterial Agent NDA Submission Targeted For 2003

Lilly expects to file an NDA for the antibacterial glycopeptide oritavancin by 2003, Senior VP-Pharmaceutical Products John Lechleiter, PhD, told the J.P. Morgan H&Q Healthcare Conference in San Francisco Jan. 8.

Lilly Is Attentive To ADHD: Tomoxetine Into Phase III; 2001 NDA Planned

Tomoxetine for attention deficit hyperactivity disorder could be the next neuroscience entry from Lilly, building on the Prozac and Zyprexa franchises.

Table

View full table

Tags:
UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By